The role of imaging in the management of progressive glioblastoma

A systematic review and evidence-based clinical practice guideline

Timothy Charles Ryken, Nafi Aygun, Johnathan Morris, Marin Schweizer, Rajeshwari Nair, Cassandra Spracklen, Steven N. Kalkanis, Jeffrey J. Olson

Research output: Contribution to journalArticle

Abstract

Question: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? Target population: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. Recommendations Level II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. Level II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. Level III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. Level III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

Original languageEnglish (US)
Pages (from-to)435-460
Number of pages26
JournalJournal of Neuro-Oncology
Volume118
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Evidence-Based Practice
Glioblastoma
Practice Guidelines
Neoplastic Processes
Neoplasms
Health Services Needs and Demand
Gadolinium
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Magnetic Resonance Spectroscopy
Therapeutics
Magnetic Resonance Imaging

Keywords

  • Glioblastoma
  • Imaging
  • Malignant glioma
  • Practice guideline
  • Progression
  • Pseudo-progression
  • Radiology
  • Recurrence
  • Systematic review

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

The role of imaging in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. / Ryken, Timothy Charles; Aygun, Nafi; Morris, Johnathan; Schweizer, Marin; Nair, Rajeshwari; Spracklen, Cassandra; Kalkanis, Steven N.; Olson, Jeffrey J.

In: Journal of Neuro-Oncology, Vol. 118, No. 3, 2014, p. 435-460.

Research output: Contribution to journalArticle

Ryken, Timothy Charles ; Aygun, Nafi ; Morris, Johnathan ; Schweizer, Marin ; Nair, Rajeshwari ; Spracklen, Cassandra ; Kalkanis, Steven N. ; Olson, Jeffrey J. / The role of imaging in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. In: Journal of Neuro-Oncology. 2014 ; Vol. 118, No. 3. pp. 435-460.
@article{e8c5c785ef9e4929a31c09decbc8218b,
title = "The role of imaging in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline",
abstract = "Question: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? Target population: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. Recommendations Level II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. Level II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. Level III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. Level III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.",
keywords = "Glioblastoma, Imaging, Malignant glioma, Practice guideline, Progression, Pseudo-progression, Radiology, Recurrence, Systematic review",
author = "Ryken, {Timothy Charles} and Nafi Aygun and Johnathan Morris and Marin Schweizer and Rajeshwari Nair and Cassandra Spracklen and Kalkanis, {Steven N.} and Olson, {Jeffrey J.}",
year = "2014",
doi = "10.1007/s11060-013-1330-0",
language = "English (US)",
volume = "118",
pages = "435--460",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - The role of imaging in the management of progressive glioblastoma

T2 - A systematic review and evidence-based clinical practice guideline

AU - Ryken, Timothy Charles

AU - Aygun, Nafi

AU - Morris, Johnathan

AU - Schweizer, Marin

AU - Nair, Rajeshwari

AU - Spracklen, Cassandra

AU - Kalkanis, Steven N.

AU - Olson, Jeffrey J.

PY - 2014

Y1 - 2014

N2 - Question: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? Target population: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. Recommendations Level II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. Level II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. Level III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. Level III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

AB - Question: Which imaging techniques most accurately differentiate true tumor progression from pseudo-progression or treatment related changes in patients with previously diagnosed glioblastoma? Target population: These recommendations apply to adults with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. Recommendations Level II: Magnetic resonance imaging with and without gadolinium enhancement is recommended as the imaging surveillance method to detect the progression of previously diagnosed glioblastoma. Level II: Magnetic resonance spectroscopy is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma. Level III: The routine use of positron emission tomography to identify progression of glioblastoma is not recommended. Level III: Single-photon emission computed tomography imaging is recommended as a diagnostic method to differentiate true tumor progression from treatment-related imaging changes or pseudo-progression in patients with suspected progressive glioblastoma.

KW - Glioblastoma

KW - Imaging

KW - Malignant glioma

KW - Practice guideline

KW - Progression

KW - Pseudo-progression

KW - Radiology

KW - Recurrence

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84903821603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903821603&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1330-0

DO - 10.1007/s11060-013-1330-0

M3 - Article

VL - 118

SP - 435

EP - 460

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -